Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including central nervous system diseases, oncology, anti-infectives, and metabolic diseases. Its principal products include Mailingda, a drug for the treatment of chronic myelogenous leukemia; and Ameile, Hansoh Xinfu, Pulaile, Zefei, Xinwei, Xinmei, Xintai, Tanneng, Oulanning, Ameining, Zetan, Hengjie, Hengsen, Fulaimei, Fulaidi, and Ruibote drugs. The company serves pharmaceutical product distributors. It has a strategic collaboration with Scynexis, Inc. to develop and commercialize ibrexafungerp for treatment of vaginal yeast infections; and strategic collaboration with Keros to develop, manufacture, and commercialize KER-050 for treatment of cytopenias, anemia, and thrombocytopenia. The company also has a collaboration with Olix Pharmaceuticals for development of drug candidates for cardiovascular, metabolic, and other diseases associated with the liver; and strategic collaboration with Silence Therapeutics plc to develop siRNAs for three targets leveraging Silence's mRNAi GOLD platform. The company was founded in 1995 and is headquartered in Lianyungang, the People's Republic of China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
Revenue of Hansoh Pharmaceutical Group Company Limited (3692.HK)
Revenue in 2023 (TTM): $1.3 B
According to Hansoh Pharmaceutical Group Company Limited's latest financial reports the company's current revenue (TTM) is $1.3 B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Hansoh Pharmaceutical Group Company Limited
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $1.3 B | $1.17 B | $539.57 M | $483.93 M | $421.14 M |
| 2022 | $1.21 B | $1.09 B | $376.72 M | $378.85 M | $331.99 M |
| 2021 | $1.28 B | $1.16 B | $396.27 M | $424.04 M | $348.59 M |
| 2020 | $1.12 B | $1.01 B | $384.1 M | $398.11 M | $330.09 M |
| 2019 | $1.12 B | $1.02 B | $380.87 M | $385.6 M | $328.52 M |
| 2018 | $992.26 M | $914.77 M | $318.58 M | $296.73 M | $244.53 M |
| 2017 | $794.8 M | $736.31 M | $265.55 M | $248.35 M | $205.01 M |
| 2016 | $698.1 M | $647.05 M | $247.86 M | $231.84 M | $189.66 M |